-
1.发明申请公开(公告)号：US20180022775A1
公开(公告)日：2018-01-25
申请号：US15660470
申请日：2017-07-26
CPC分类号： C07J7/009 , C07B2200/13 , C07J3/005 , C07J31/006 , C07J71/0005 , C07J71/0031 , Y10T428/2982
摘要： The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
-
公开(公告)号：US11406596B2
公开(公告)日：2022-08-09
申请号：US16934807
申请日：2020-07-21
发明人： Jean-Michel Bukowski , Akshay Nadkarni , José L. Boyer , Brigitte Duquesroix-Chakroun , Tomas Navratil
IPC分类号： A61K9/08 , A61P27/02 , A61K9/00 , A61K31/567 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/38 , B82Y5/00
摘要： A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
公开(公告)号：US20210290617A1
公开(公告)日：2021-09-23
申请号：US17332814
申请日：2021-05-27
发明人： Mark Barry ABELSON , Matthew J. CHAPIN , Paul GOMES , George MINNO , Jackie NICE
IPC分类号： A61K31/495 , A61K9/08 , A61K31/4965 , A61K31/56 , A61K9/00 , A61K31/4174 , A61K31/569 , A61K47/10 , A61K47/02 , A61K47/26 , A61K47/38
摘要： The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
-
公开(公告)号：US10987352B2
公开(公告)日：2021-04-27
申请号：US16839954
申请日：2020-04-03
发明人： Mark Barry Abelson , Matthew J. Chapin , Paul Gomes , George Minno , Jackie Nice
IPC分类号： A61K31/495 , A61K31/569 , A61K31/4174 , A61K31/56 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/38 , A61K9/08 , A61K31/4965 , A61K9/00
摘要： The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
-
公开(公告)号：US20210023001A1
公开(公告)日：2021-01-28
申请号：US16934807
申请日：2020-07-21
发明人： Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号： A61K9/08 , A61K31/567 , A61K47/38 , A61K47/02 , A61K47/18 , A61K47/26 , A61K47/10 , A61P27/02 , A61K9/00
摘要： A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
公开(公告)号：US20200297719A1
公开(公告)日：2020-09-24
申请号：US16839954
申请日：2020-04-03
发明人： Mark Barry ABELSON , Matthew J. CHAPIN , Paul GOMES , George MINNO , Jackie NICE
IPC分类号： A61K31/495 , A61K9/08 , A61K31/4965 , A61K31/56 , A61K9/00 , A61K31/4174 , A61K31/569 , A61K47/10 , A61K47/02 , A61K47/26 , A61K47/38
摘要： The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
-
公开(公告)号：US20220323352A1
公开(公告)日：2022-10-13
申请号：US17850515
申请日：2022-06-27
发明人： Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号： A61K9/08 , A61P27/02 , A61K9/00 , A61K31/567 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/38
摘要： A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
公开(公告)号：US10675279B2
公开(公告)日：2020-06-09
申请号：US16001679
申请日：2018-06-06
发明人： Mark Barry Abelson , Matthew J. Chapin , Paul Gomes , George Minno , Jackie Nice
IPC分类号： A61K31/495 , A61K31/569 , A61K31/4174 , A61K31/4965 , A61K31/56 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/38 , A61K9/00 , A61K9/08
摘要： The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
-
公开(公告)号：US20170079957A1
公开(公告)日：2017-03-23
申请号：US15366559
申请日：2016-12-01
IPC分类号： A61K31/4174 , A61K47/02 , A61K47/18 , A61K9/00 , A61K31/047
CPC分类号： A61K31/4174 , A61K9/0004 , A61K9/0048 , A61K31/045 , A61K31/047 , A61K31/70 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/186
摘要： The invention features topical formulations comprising an osmotically active agent and/or a vasoconsgtrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
-
公开(公告)号：US20220241296A1
公开(公告)日：2022-08-04
申请号：US17629267
申请日：2020-07-21
发明人： Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号： A61K31/569 , A61K9/10 , A61K9/00 , A61K47/38 , A61K47/26 , A61K47/18 , A61K47/02 , A61K47/10 , A61P27/04
摘要： The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.016 秒)
